What changed: Early triple-negative breast cancer
Every dated change on the records linked to Early triple-negative breast cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Trial result3Milestone6This record1
September 2026 · 1
2024 · 1
2021 · 2
2020 · 3
- 2020Trial resultIMpassion031IMpassion031 reported
Pathological complete response 58% vs 41% (all patients); 69% vs 49% in PD-L1-positive disease.
- 2020Trial resultKEYNOTE-522KEYNOTE-522 reported
EFS HR 0.
- 2020MilestoneKEYNOTE-522KEYNOTE-522 and IMpassion031: immunotherapy raises pathological complete response
A milestone in how this cancer is treated.